share_log

Today's biggest pre-market stock movers: Puxin, Jasper Therapeutics, Waitr Holdings and more

Today's biggest pre-market stock movers: Puxin, Jasper Therapeutics, Waitr Holdings and more

今天最大的盤前股票推動者：樸新教育、賈斯珀治療公司、維特控股等
Benzinga Real-time News ·  2021/10/13 07:58  · 異動

Gainers

贏家


Losers

失敗者

  • $Neuronetics Inc(STIM.US)$ shares fell 26.9% to $4.68 in pre-market trading after the company lowered its sales guidance. BTIG downgraded Neuronetics from Buy to Neutral.

  • $Regulus Therapeutics Inc(RGLS.US)$ shares fell 25% to $0.57 in pre-market trading after the company announced a strategic prioritization of its next-generation candidate, RGLS8429, for the treatment of ADPKD. The company's previous ADPKD candidate, RGLS4326, will no longer be advanced.

  • $CytoSorbents Corp(CTSO.US)$ shares fell 9.8% to $6.25 in pre-market trading after the company reported preliminary Q3 results and received full FDA Investigational Device Exemption approval to begin US STAR-D trial on apixaban and rivaroxaban removal by DrugSorb-ATR antithrombotic removal system during urgent cardiothoracic surgery.

  • $NUTRIBAND INC(NTRB.US)$ fell 8.7% to $8.86 in pre-market trading. Nutriband shares jumped 31% on Tuesday after the company announced it signed an exclusive manufacturing agreement for Diocheck visual COVID-19 antibody indicator patch.

  • $NRX Pharmaceuticals(NRXP.US)$ fell 7.8% to $10.06 in pre-market trading. NRX Pharmaceuticals shares jumped 61% on Tuesday after the company announced progress on the worldwide commercial scale development of ZYESAMI.

  • $Apollo Endosurgery Inc(APEN.US)$ fell 7.6% to $7.84 in pre-market trading after the company reported pricing of $65 million public offering of common stock.

  • $ZIVO BIOSCIENCE(ZIVO.US)$ fell 6.5% to $4.19 in pre-market trading after gaining over 18% on Tuesday.

  • $CRISPR Therapeutics AG(CRSP.US)$ shares fell 5.8% to $96.70 in pre-market trading after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies.

  • $Neuronetics Inc.(STIM.US)$在該公司下調銷售指引後，股價在盤前交易中下跌26.9%，至4.68美元。BTIG將Neuronetics評級從買入下調至中性。

  • $Regulus治療公司(RGLS.US)$在盤前交易中，該公司股價下跌25%，至0.57美元，此前該公司宣佈對其治療ADPKD的下一代候選藥物RGLS8429進行戰略優先排序。該公司之前的ADPKD候選人RGLS4326將不再高級。

  • $CytoSorbents Corp(CTSO.US)$在盤前交易中，該公司股價下跌9.8%，至6.25美元，此前該公司報告了第三季度的初步業績，並獲得FDA全面的調查設備豁免批准，開始在美國STAR-D試驗中使用DrugSorb-ATR抗血栓清除系統在緊急心胸手術期間去除apixaban和rivaroxaban。

  • $NUTRIBAND Inc.(NTRB.US)$在盤前交易中，該股下跌8.7%，至8.86美元。週二，在公司宣佈簽署了Diocheck視覺新冠肺炎抗體指示器貼片的獨家制造協議後，Nutriband的股價上漲了31%。

  • $NRX製藥公司(NRXP.US)$在盤前交易中下跌7.8%，至10.06美元。NRX PharmPharmticals股價週二大漲61%，此前該公司宣佈ZYESAMI的全球商業規模開發取得進展。

  • $阿波羅內科手術公司(APEN.US)$在盤前交易中，該公司股價下跌7.6%，至7.84美元，此前該公司公佈普通股公開發行定價為6500萬美元。

  • $Zivo Bioscience(ZIVO.US)$在週二上漲超過18%後，該公司在盤前交易中下跌6.5%，至4.19美元。

  • $CRISPR Treateutics AG(CRSP.US)$在盤前交易中，該公司股價下跌5.8%，至96.70美元，此前該公司公佈了CTX110治療復發或難治性CD19+B細胞惡性腫瘤的第一階段碳試驗結果。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論